[Skip to Content]
[Skip to Content Landing]
Article
March 1985

LevobunololA Three-Month Efficacy Study in the Treatment of Glaucoma and Ocular Hypertension

Author Affiliations

From the Pacific Eye Foundation, Seattle (Dr Bensinger), and the Pacific Medical Center of Seattle (Dr Gofman); the Scheie Eye Institute, Philadelphia (Dr Keates); and the University of California and Allergan Pharmaceuticals Inc, Irvine (Drs Novack and Duzman).

Arch Ophthalmol. 1985;103(3):375-378. doi:10.1001/archopht.1985.01050030071024
Abstract

• The ocular hypotensive effect and the safety of levobunolol hydrochloride (0.5% and 1%) were compared with vehicle in this double-masked study of 42 patients with chronic open-angle glaucoma or ocular hypertension. After a washout of ocular hypotensive medication, patients received one of the three test treatments in both eyes twice daily for three months. Both concentrations of levobunolol produced significant reductions in intraocular pressure, while decreases in vehicle-treated patients were minimal. Over the three-month study period, average pressure reductions were approximately 9.0 mm Hg in patients receiving either concentration of levobunolol and 0.5 mm Hg in patients receiving vehicle. Fewer patients were terminated from the study for inadequately controlled intraocular pressure in the levobunolol groups than in the vehicle group. No patients were terminated for drug-related adverse experiences.

×